HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
m3Ws41xSXy3v0z8c